By Amy Killelea, Associate Director, Health Care Access, NASTAD
After a three and a half year wait – and several near-death experiences along the way – open enrollment under the Affordable Care Act (ACA) is finally here. On October 1st, 2013 the Marketplaces officially open for business, and millions of people will begin to apply for new public and private insurance coverage options. At this point, we all know the incredible opportunities to expand HIV and viral hepatitis prevention, care, and treatment that are at stake. Now is where the rubber meets the road as federal, state, and local advocates, providers, and programs roll up their sleeves and prepare for full implementation. Below are four action items the HIV and viral hepatitis community should be focusing on as we leap into open enrollment and beyond: Continue reading
By Ann Lefert, National Alliance of State and Territorial AIDS Directors and Bill McColl, AIDS United, Co-Chairs of the Ryan White Work Group, Federal AIDS Policy Partnership
As Co-Chairs of the Ryan White Work Group, we wanted to provide you with an update on the Ryan White Program. As you know, the current authorization ends on September 30, 2013. However, there is no “sunset” provision in the legislation. Therefore even if Congress does not take action, the Ryan White Program will remain a part of the law allowing funding to continue to be appropriated through the annual congressional appropriations process. Continue reading
FOR IMMEDIATE RELEASE
Contact: Meico Whitlock
August 26, 2013, Washington, DC – The ADAP Crisis Task Force (ACTF) has reached a new pricing agreement with ViiV Healthcare for AIDS Drug Assistance Programs (ADAPs) for Tivicay® (dolutegravir) for the treatment of HIV-1 infected individuals. The agreed-upon ADAP direct purchase price for Tivicay®, negotiated between the ACTF and ViiV, is substantially lower than the wholesale acquisition cost (WAC), reflecting voluntary discounts that are also significantly below the mandated 340B pricing of the medication.
FOR IMMEDIATE RELEASE
Contact: Murray Penner
July 29, 2013, Washington, DC – As part of ongoing efforts by the ADAP Crisis Task Force (Task Force) and the pharmaceutical industry to address the continued need for access to HIV antiretroviral medicines through AIDS Drug Assistance Programs (ADAPs), the Task Force announced today that it has reached agreement with AbbVie, Gilead Sciences, Merck, and ViiV Healthcare to extend the voluntary discounts/rebates and price freezes available to all state ADAPs through December 31, 2014.